Predictive Value of SLCO1B1 c.521T>C Polymorphism on Observed Changes in the Treatment of 1136 Statin-Users.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: MDPI Country of Publication: Switzerland NLM ID: 101551097 Publication Model: Electronic Cited Medium: Internet ISSN: 2073-4425 (Electronic) Linking ISSN: 20734425 NLM ISO Abbreviation: Genes (Basel) Subsets: MEDLINE
    • Publication Information:
      Original Publication: Basel : MDPI
    • Subject Terms:
      Hydroxymethylglutaryl-CoA Reductase Inhibitors*/therapeutic use ; Drug-Related Side Effects and Adverse Reactions*; Humans ; Cross-Sectional Studies ; Retrospective Studies ; Polymorphism, Single Nucleotide ; Liver-Specific Organic Anion Transporter 1/genetics
    • Abstract:
      Pharmacogenomic testing is a method to prevent adverse drug reactions. Pharmacogenomics could be relevant to optimize statin treatment, by identifying patients at high risk for adverse drug reactions. We aim to investigate the clinical validity and utility of pre-emptive pharmacogenomics screening in primary care, with SLCO1B1 c.521T>C as a risk factor for statin-induced adverse drug reactions. The focus was on changes in therapy as a proxy for adverse drug reactions observed in statin-users in a population-based Dutch cohort. In total, 1136 statin users were retrospectively genotyped for the SLCO1B1 c.521T>C polymorphism (rs4149056) and information on their statin dispensing was evaluated as cross-sectional research. Approximately half of the included participants discontinued or switched their statin treatment within three years. In our analyses, we could not confirm an association between the SLCO1B1 c.521T>C genotype and any change in statin therapy or arriving at a stable dose sooner in primary care. To be able to evaluate the predictive values of SLCO1B1 c.521T>C genotype on adverse drug reactions from statins, prospective data collection of actual adverse drug reactions and reasons to change statin treatment should be facilitated.
    • References:
      PLoS Curr. 2013 Dec 04;5:. (PMID: 24459608)
      Genet Med. 2014 Nov;16(11):810-9. (PMID: 24810685)
      Pharmacol Res. 2014 Oct;88:3-11. (PMID: 24657242)
      Pharmacogenomics J. 2018 Dec;18(6):721-729. (PMID: 30250148)
      Br J Clin Pharmacol. 2014 Sep;78(3):454-66. (PMID: 25069381)
      Pharmacogenomics. 2016;17(2):163-80. (PMID: 26670324)
      Atherosclerosis. 2010 Jul;211(1):28-9. (PMID: 20347093)
      Clin Pharmacol Ther. 2011 Feb;89(2):210-6. (PMID: 21178985)
      Pharmacotherapy. 2013 Jul;33(7):765-75. (PMID: 23649914)
      Clin Pharmacol Ther. 2019 Aug;106(2):360-373. (PMID: 30137643)
      Circ Genom Precis Med. 2018 Sep;11(9):e002228. (PMID: 30354330)
      Int J Epidemiol. 2017 Dec 1;46(6):1751-1751g. (PMID: 29040549)
      Osteoporos Int. 2015 Jun;26(6):1831-40. (PMID: 25822104)
      Eur J Clin Pharmacol. 2012 Mar;68(3):273-9. (PMID: 21928084)
      Eur J Hum Genet. 2021 Mar;29(3):365-377. (PMID: 33223530)
      Dermatoendocrinol. 2010 Apr;2(2):77-84. (PMID: 21547103)
      Genet Med. 2006 Jul;8(7):448-50. (PMID: 16845278)
      Genes Nutr. 2014 Nov;9(6):434. (PMID: 25322899)
      J Clin Oncol. 2016 Jan 20;34(3):227-34. (PMID: 26573078)
      PLoS One. 2013 Oct 16;8(10):e77587. (PMID: 24147031)
      Clin Pharmacol Ther. 2011 May;89(5):662-73. (PMID: 21412232)
      N Engl J Med. 2008 Aug 21;359(8):789-99. (PMID: 18650507)
      Cardiovasc Res. 2018 Jul 1;114(8):1073-1081. (PMID: 29878063)
      Nat Commun. 2014 Oct 28;5:5068. (PMID: 25350695)
      Clin Pharmacol Ther. 2014 Dec;96(6):655-7. (PMID: 25399714)
      Int J Epidemiol. 2008 Dec;37(6):1236-41. (PMID: 18238821)
      Am Heart J. 2014 Jul;168(1):6-15. (PMID: 24952854)
      Pharmacogenomics J. 2012 Jun;12(3):233-7. (PMID: 21243006)
      Genet Med. 2016 Jul;18(7):672-4. (PMID: 26656648)
      Ann Pharmacother. 2011 May;45(5):576-81. (PMID: 21521863)
      Clin Pharmacol Ther. 2013 Dec;94(6):695-701. (PMID: 23942138)
      Clin Pharmacol Ther. 2010 Jan;87(1):130-3. (PMID: 19890253)
      Eur Heart J. 2015 May 1;36(17):1012-22. (PMID: 25694464)
      Med Sci Monit. 2015 May 20;21:1454-9. (PMID: 25992810)
      Clin Pharmacol Ther. 2014 Oct;96(4):423-8. (PMID: 24918167)
      Eur J Clin Pharmacol. 2014 May;70(5):539-47. (PMID: 24595600)
      Pharmacogenet Genomics. 2014 Jan;24(1):43-51. (PMID: 24263182)
      J Pers Med. 2020 Dec 21;10(4):. (PMID: 33371313)
      Front Pharmacol. 2017 Aug 23;8:555. (PMID: 28878673)
      Genes (Basel). 2019 May 29;10(6):. (PMID: 31146504)
      Ned Tijdschr Geneeskd. 2010;154:A1684. (PMID: 21435278)
      Atherosclerosis. 2010 Jun;210(2):337-43. (PMID: 20042189)
      Expert Opin Drug Saf. 2010 Jul;9(4):603-21. (PMID: 20377474)
      Genet Med. 2011 Dec;13(12):987-95. (PMID: 22095251)
      Curr Atheroscler Rep. 2016 May;18(5):20. (PMID: 26973129)
      Eur Heart J. 2013 Apr;34(13):982-92. (PMID: 23100282)
      Front Genet. 2020 Jan 31;11:10. (PMID: 32076434)
      Atherosclerosis. 2015 May;240(1):260-71. (PMID: 25818852)
      Int J Clin Pharm. 2015 Dec;37(6):1095-103. (PMID: 26159317)
      J Am Coll Cardiol. 2009 Oct 20;54(17):1609-16. (PMID: 19833260)
      Lancet. 2007 Nov 24;370(9601):1781-90. (PMID: 17559928)
      Heart. 2004 Sep;90(9):1065-6. (PMID: 15310708)
      Physiol Res. 2014;63(Suppl 3):S327-34. (PMID: 25428737)
    • Contributed Indexing:
      Keywords: adverse drug reactions; pharmacogenomics; primary care; screening; statins
    • Accession Number:
      0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
      0 (SLCO1B1 protein, human)
      0 (Liver-Specific Organic Anion Transporter 1)
    • Publication Date:
      Date Created: 20230225 Date Completed: 20230228 Latest Revision: 20231117
    • Publication Date:
      20231117
    • Accession Number:
      PMC9957000
    • Accession Number:
      10.3390/genes14020456
    • Accession Number:
      36833383